Viatris exits the divestiture hangover and re-rates as a de-levered, cash-rich “total return” pharma—if 2026 specialty approvals and China execution hold.
Overview
Viatris enters 2026 as a leaner, more focused company after completing major divestitures and debt reduction, and Q1 2026 results provide evidence of stabilization and renewed growth. Revenue of $3.52B beat expectations and represented 3% operational growth, while adjusted EBITDA rose 10% to $1.05B and adjusted EPS reached $0.59. The dramatic GAAP swing versus Q1 2025 largely reflects the absence of a prior-year $2.9B goodwill impairment, improving earnings visibility for investors. Growth is increasingly polarized: Greater China is the standout (+18% operational, $680M sales) supported by a pivot to retail/e-commerce, while Europe and JANZ face pricing/regulatory pressure. The Phase 2 roadmap targets a 4% organic revenue run-rate by 2030, powered by specialty pillars and a 2026 pipeline catalyst calendar (Xulane Lo, MR-141, fast-acting meloxicam). With leverage reduced to ~2.9x and >$2.5B 2026 cash available for deployment, management is shifting capital toward buybacks, dividends, and accretive BD to drive per-share compounding through 2030.